Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for MNKD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 2002. Start Trial.
Date Value
June 30, 2026 434.28M
March 31, 2026 434.72M
December 31, 2025 471.27M
September 30, 2025 187.77M
June 30, 2025 114.84M
March 31, 2025 115.57M
December 31, 2024 154.80M
September 30, 2024 344.92M
June 30, 2024 336.45M
March 31, 2024 372.62M
December 31, 2023 360.96M
September 30, 2023 382.40M
June 30, 2023 384.83M
March 31, 2023 383.83M
December 31, 2022 388.36M
September 30, 2022 383.62M
June 30, 2022 384.40M
March 31, 2022 386.46M
December 31, 2021 388.67M
September 30, 2021 287.45M
June 30, 2021 291.62M
March 31, 2021 338.72M
December 31, 2020 130.70M
September 30, 2020 85.23M
June 30, 2020 125.46M
Date Value
March 31, 2020 123.33M
December 31, 2019 123.65M
September 30, 2019 128.78M
June 30, 2019 102.95M
March 31, 2019 103.56M
December 31, 2018 100.03M
September 30, 2018 100.12M
June 30, 2018 100.20M
March 31, 2018 105.46M
December 31, 2017 112.92M
September 30, 2017 116.17M
June 30, 2017 116.16M
March 31, 2017 86.01M
December 31, 2016 86.00M
September 30, 2016 157.26M
June 30, 2016 147.12M
March 31, 2016 145.97M
December 31, 2015 139.50M
September 30, 2015 120.78M
June 30, 2015 177.77M
March 31, 2015 149.11M
December 31, 2014 148.88M
September 30, 2014 122.15M
June 30, 2014 148.41M
March 31, 2014 148.18M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
United Therapeutics Corp. 0.00
ACADIA Pharmaceuticals, Inc. 59.55M
Gilead Sciences, Inc. 26.25B
Vertex Pharmaceuticals, Inc. 1.978B
Ocugen, Inc. 4.788M